Prostate Cancer
How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study.
February 28, 2025
Acceptability of a nurse-led survivorship intervention for men with prostate cancer receiving androgen deprivation therapy: A qualitative exploratory study.
February 28, 2025
Race and Ethnicity, Lifestyle, Diet, and Survival in Patients With Prostate Cancer.
February 28, 2025
Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET.
February 28, 2025
TP53 Deficiency in the Natural History of Prostate Cancer.
February 27, 2025
Cell Models of Castration Resistant and High Dose Testosterone-Resistant Prostate Cancer Recapitulate the Heterogeneity of Response Observed in Clinical Practice.
February 27, 2025
Radical Prostatectomy in Multimodal Setting: Current Role of Neoadjuvant and Adjuvant Hormonal or Chemotherapy-Based Treatments.
February 27, 2025
Bridging the Gap: Enhancing Prostate Cancer Survivorship and Advocacy Among Ethnically Diverse Black Men Through Community Town Halls.
February 26, 2025
Assessing the Impact of Transition and Peripheral Zone PSA Densities Over Whole-Gland PSA Density for Prostate Cancer Detection on Multiparametric MRI.
February 26, 2025
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.
February 26, 2025
Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer During Serial Therapy.
February 26, 2025
Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer.
February 25, 2025
Association between the use of proton pump inhibitors and serum PSA levels in the general U.S. population.
February 25, 2025